Eli Lilly partners with telehealth company Ro to distribute discounted Zepbound vials at $399/month, while competitor Novo ...

Demis Hassabis has no interest in a laboratory. The Nobel Prize-winning artificial intelligence pioneer is betting big on ...

End­points News has once again reached out to a lengthy ros­ter of biotech ex­ecs to take their pulse on what’s ahead for the ...

Pfizer touts Ibrance’s status as a standard of care in HR-positive, HER2-negative metastatic breast cancer. Now the company ...

Columvi combo in DLBCL, while AnaptysBio's ANB032 fails in atopic dermatitis. Essential Pharma gets €1.2B financing deal.

Keros Therapeutics halts two dosing arms of cibotercept Phase 2 trial due to pericardial effusion safety concerns; continues ...

Lonza CEO Wolfgang Wienand plans to exit capsules/health ingredients market and restructure into three business units, with ...

Illumina exec Vik Vaz as CEO to advance biological detection tech for drug research. The company uses what it calls ...

Corcept Therapeutics' dazucorilant fails Phase 2 ALS trial after missing primary endpoint, following October's Cushing's ...

New drugs in the US were, on average, approved months before winning approval in the EU, according to new data from The IQVIA ...

Another trial for SIGA Technologies' mpox antiviral has failed, and all enrollment has been stopped, the NIH's National ...

Candel Therapeutics’ viral immunotherapy candidate passed a late-stage test in certain patients with prostate cancer, sending ...